vidarabine has been researched along with T-Cell Lymphoma in 15 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (20.00) | 18.2507 |
| 2000's | 9 (60.00) | 29.6817 |
| 2010's | 2 (13.33) | 24.3611 |
| 2020's | 1 (6.67) | 2.80 |
| Authors | Studies |
|---|---|
| Akiyama, M; Goto, H; Hasegawa, D; Honda, T; Kumamoto, T; Ogawa, S; Takagi, M; Terao, YM; Yamaoka, M; Yoshida, K | 1 |
| Chadwick, H; Counsell, N; Evans, K; Johnson, RJ; Pottinger, BT; Rudin, CE; Smith, P; Townsend, W; Wickham, C | 1 |
| Chim, CS; Kwong, YL; Loong, F; Ng, WK | 1 |
| Chow, KU; Dreyling, M; Hess, G; Jäger, E; Kim, SZ; Krause, SW; Kruse, J; Mitrou, PS; Napieralski, S; Rech, J; Soekler, M; Subklewe, M; Weidmann, E; Weisel, KC | 1 |
| Bourikas, G; Kaloutsi, V; Margaritis, D; Pantelidou, D; Spanudakis, E; Tsatalas, C | 1 |
| Gazelka, H; Go, RS; Hogan, JD; Wester, SM | 1 |
| Arase, Y; Hamaki, T; Hayashi, M; Igarashi, M; Ishibashi, T; Kami, M; Kusumi, E; Miyakoshi, S; Morinaga, S; Mutou, Y; Shimamura, K; Takaue, Y | 1 |
| Au, WY; Chan, LC; Kwong, YL; Liang, R | 1 |
| Forman, SJ; Kogut, N; Krishnan, A; Nademanee, A; Nakamura, R; Patane, K; Popplewell, L; Rodriguez, R; Ruel, N; Sarkodee-Adoo, C; Smith, E; Zain, J | 1 |
| Feldman, EJ; Keating, MJ | 1 |
| Bamborschke, S; Diehl, V; Fätkenheuer, G; Lehrke, R; Re, D; Reiser, M; Salzberger, B; Schröder, R; Tesch, H | 1 |
| Hast, R; Hjalmar, V; Jacobsson, B; Petrescu, A | 1 |
| Catovsky, D; Dearden, CE; Matutes, E | 1 |
| Foss, FM | 1 |
| Bourikas, G; Kaloutsi, V; Kotsianidis, I; Margaritis, D; Martinis, G; Tsatalas, C | 1 |
2 review(s) available for vidarabine and T-Cell Lymphoma
| Article | Year |
|---|---|
Fludarabine in the treatment of lymphoproliferative malignancies.
Topics: Antineoplastic Agents; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, B-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Lymphoproliferative Disorders; Vidarabine | 1993 |
Combination therapy with purine nucleoside analogs.
Topics: Adult; Aged; Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials as Topic; Deoxyadenosines; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Interferons; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Middle Aged; Pentostatin; Purine Nucleosides; Treatment Outcome; Vidarabine | 2000 |
2 trial(s) available for vidarabine and T-Cell Lymphoma
| Article | Year |
|---|---|
A phase II clinical trial of fludarabine and cyclophosphamide followed by thalidomide for angioimmunoblastic T-cell lymphoma. An NCRI clinical trial. CRUK number C17050/A5320.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease Progression; Drug Administration Schedule; Female; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Male; Middle Aged; Survival Analysis; Thalidomide; Vidarabine | 2016 |
A phase II study of alemtuzumab, fludarabine, cyclophosphamide, and doxorubicin (Campath-FCD) in peripheral T-cell lymphomas.
Topics: Adult; Aged; Alemtuzumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Neoplasm; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Disease-Free Survival; Doxorubicin; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Recurrence; Treatment Outcome; Vidarabine | 2010 |
11 other study(ies) available for vidarabine and T-Cell Lymphoma
| Article | Year |
|---|---|
Successful treatment of hepatosplenic T-cell lymphoma with fludarabine, high-dose cytarabine and subsequent unrelated umbilical cord blood transplantation.
Topics: Child, Preschool; Cord Blood Stem Cell Transplantation; Cyclin-Dependent Kinase Inhibitor p16; Cyclophosphamide; Cytarabine; DNA-Binding Proteins; Etoposide; ETS Translocation Variant 6 Protein; Female; Gene Deletion; Humans; Liver Neoplasms; Lymphoma, T-Cell; PAX5 Transcription Factor; Prognosis; Proto-Oncogene Proteins c-ets; Remission Induction; Repressor Proteins; Splenic Neoplasms; Transplantation Conditioning; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2022 |
Use of fludarabine-containing chemotherapeutic regimen results in durable complete remission of subcutaneous panniculitis-like T-cell lymphoma.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Lymphoma, T-Cell; Male; Middle Aged; Mitoxantrone; Panniculitis; Skin Neoplasms; Vidarabine | 2008 |
Treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine.
Topics: Antineoplastic Agents; Female; Humans; Hypergammaglobulinemia; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Middle Aged; Remission Induction; Vidarabine | 2003 |
Subcutaneous panniculitis-like T-cell lymphoma: complete remission with fludarabine.
Topics: Aged; Antineoplastic Agents; Humans; Lymphoma, T-Cell; Male; Necrosis; Panniculitis; Vidarabine | 2003 |
Non-myeloablative hematopoietic stem cell transplantation for the treatment of adult T-cell lymphoma in a patient with advanced hepatic impairment.
Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Cyclophosphamide; Hematopoietic Stem Cell Transplantation; Hepatitis B; Humans; Liver Cirrhosis; Lymphoma, T-Cell; Male; Middle Aged; Time Factors; Vidarabine | 2003 |
Myelodysplastic syndrome and acute myeloid leukemia after treatment with fludarabine, mitoxantrone, and dexamethasone.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Dexamethasone; Female; Humans; Leukemia, Myeloid, Acute; Lymphoma, B-Cell; Lymphoma, T-Cell; Male; Mitoxantrone; Myelodysplastic Syndromes; Neoplasms, Second Primary; Vidarabine | 2006 |
Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma.
Topics: Adolescent; Adult; Aged; Busulfan; Cause of Death; Cohort Studies; Cyclophosphamide; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Graft vs Host Disease; Hepatic Veno-Occlusive Disease; Humans; Infections; Kaplan-Meier Estimate; Lung Diseases, Interstitial; Lymphoma, Follicular; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Mantle-Cell; Lymphoma, Non-Hodgkin; Lymphoma, T-Cell; Male; Melphalan; Middle Aged; Peripheral Blood Stem Cell Transplantation; Postoperative Complications; Proportional Hazards Models; Reoperation; Retrospective Studies; Risk Factors; Survival Analysis; Transplantation Conditioning; Transplantation, Homologous; Treatment Outcome; Vidarabine; Whole-Body Irradiation | 2006 |
Two cases of toxoplasmic encephalitis in patients with acute T-cell leukaemia and lymphoma.
Topics: Antineoplastic Combined Chemotherapy Protocols; Female; HIV Seronegativity; Humans; Immunocompromised Host; Leukemia-Lymphoma, Adult T-Cell; Lymphoma, T-Cell; Male; Meningoencephalitis; Methotrexate; Middle Aged; Toxoplasmosis; Vidarabine | 1999 |
Successful treatment with fludarabine in two cases of angioimmunoblastic lymphadenopathy with dysproteinemia.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Female; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Middle Aged; Remission Induction; Vidarabine | 1999 |
Clinical overview of pentostatin (Nipent) use in lymphoid malignancies.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Resistance, Neoplasm; Follow-Up Studies; Humans; Immunosuppressive Agents; Leukemia; Leukemia, B-Cell; Leukemia, Hairy Cell; Leukemia, Lymphocytic, Chronic, B-Cell; Leukemia, Prolymphocytic; Leukemia, T-Cell; Lymphoma; Lymphoma, B-Cell; Lymphoma, T-Cell; Pentostatin; Sezary Syndrome; Survival Rate; Vidarabine | 2000 |
Successful treatment of angioimmunoblastic lymphadenopathy with dysproteinemia-type T-cell lymphoma with fludarabine.
Topics: Antineoplastic Combined Chemotherapy Protocols; Disease-Free Survival; Drug Administration Schedule; Humans; Immunoblastic Lymphadenopathy; Lymphoma, T-Cell; Male; Middle Aged; Treatment Outcome; Vidarabine | 2001 |